Ascendis Pharma A/S (NASDAQ:ASND) is one of the 11 Best Stocks to Buy for Investment. On January 27, BofA reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND). Tazeen Ahmad at BofA retained the rating on ASND and maintained the price target at $246. BofA Reiterates Buy Rating on Ascendis Pharma, While Wells Fargo Analyst Upgrades PT on ASND adriaticfoto/Shutterstock.com In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pha ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment. On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is one of the 11 Best Stocks to Buy for Investment. On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating. Swayampakula Ramakanth from H.C. Wainwright has increased the price target on MIRM twice in a span of two weeks. H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? Ramakanth’s price ta ...

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best strong buy stocks to invest in under $5. AtaiBeckley Inc. (NASDAQ:ATAI) received a rating update from H.C. Wainwright on January 28, which reiterated a Buy rating on the stock and set a price target of $15. Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds? In another development, AtaiBeckley Inc. (NASDAQ:ATAI) was initiated with a Buy rating at Guggenheim on January 20, with the firm setting an $11 price target. Guggenhei ...

Core Viewpoint - Corvus Pharmaceuticals, Inc. (CRVS) is experiencing significant stock price growth due to positive clinical trial results for its lead candidate, soquelitinib, and has a new price target set by Mizuho Securities indicating further potential upside [1][6]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on innovative therapies for immune-related diseases [1]. Stock Performance - CRVS stock has surged by 209% over the past month following positive Phase I study results for soquelitinib, which showed a 72% reduction in the Eczema Area and Severity Index (EASI) [2][3]. - The current trading price of CRVS is $20.54, reflecting a 6.97% decrease today, with a market capitalization of approximately $1.53 billion [5]. Clinical Trial Results - The Phase I study for soquelitinib was a blinded, placebo-controlled trial involving patients who had previously undergone systemic therapy, confirming its potential as a "first-in-class" selective ITK inhibitor [4]. Financial Developments - Corvus Pharmaceuticals successfully closed an upsized public offering, raising approximately $201 million to support working capital, capital expenditures, and research and development, particularly for its Phase 3 T cell lymphoma program [3][6].

More and more it feels like companies across industries have bought into the idea that it is often best to specialize in whatever it is they do best and outsource as much of what remains as is practical. In the caseAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other tha ...

Travere Therapeutics ( TVTX ) is a San Diego-based biopharmaceutical company specialized in rare kidney and metabolic diseases, with the key product FILSPARI (sparsentan) that is fully approved for IgA Nephropathy (IgAN). It was slated for a PDUFA decision on Jan 13, 2026, for focal segmental glomerulosclerosis (FSGS), butAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresse ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Zenshine Pharmaceuticals (Nanjing) Group Co., Ltd. 征 祥 醫 藥（ 南 京 ）集 團 股 份 有 限 公 司 (the "Company") (a joint stock com ...

Sanofi (NasdaqGS:SNY) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsBen Jackson - VP of Equity ResearchBrian Foard - EVP and Head of Specialty CareDavid Reed Risinger - Senior Managing DirectorFrançois-Xavier Roger - CFOGraham Parry - Managing Director and Head of European Pharmaceuticals Equity researchHouman Ashrafian - EVP and Head of Research and DevelopmentJames Gordon - Director and Head of European Pharma, Biotech & Life Sciences Equity ResearchJames Quigley - Executive Direc ...